Prostate cancer: Platelet-to-lymphocyte ratio predicts prostate cancer prognosis

Nature Reviews Urology

Volumn 12, Issue 5, 2015, Pages 238-

  Sidaway, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HUMAN; NOTE; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; TUMOR GROWTH; LYMPHOCYTE; MALE; METABOLISM; PROSTATIC NEOPLASMS; THROMBOCYTE;

BLOOD PLATELETS; HUMANS; LYMPHOCYTES; MALE; PROSTATIC NEOPLASMS;

EID: 84930758081     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.69     Document Type: Note

References (1)

1. Langsenlehner, T. et al. Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urol. Oncol. doi:10.1016/j.urolonc.2015.02.002